These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6263476)

  • 1. Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST-2575, generation I).
    Creech RH; Mehta CR; Cohen M; Donavan M; Sponzo R; Mason BA; Skeel RT; Ahmed F; Creaven PJ; Lerner HJ; Foelsch E
    Cancer Treat Rep; 1981; 65(5-6):431-8. PubMed ID: 6263476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II.
    Ruckdeschel JC; Mehta CR; Salazar OM; Cohen M; Vogl S; Koons LS; Lerner H
    Cancer Treat Rep; 1981; 65(11-12):965-72. PubMed ID: 7028258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung.
    Davis S; Pandya MR; Rambotti P
    Cancer Treat Rep; 1980; 64(4-5):685-8. PubMed ID: 6253067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
    Aisner J; Whitacre M; Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1982 Feb; 66(2):221-30. PubMed ID: 6275987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide, vincristine, lomustine, cisplatin, and doxorubicin in the treatment of non-small cell lung cancer.
    Pearlman NW; Meyers TJ; Siebert PE; Wallner SF; Carson SD; Campbell DN; Johnson FB; Kennaugh R; Rempel P
    Cancer Treat Rep; 1983 Apr; 67(4):375-6. PubMed ID: 6303587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine.
    Mintz U; Bitran JD; Cooksey JA; Desser RK; DeMeester TR; Golomb HM
    Cancer Treat Rep; 1978 Apr; 62(4):567-9. PubMed ID: 77725
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung.
    Edmonson JH; Lagakos SW; Selawry OS; Perlia CP; Bennett JM; Muggia FM; Wampler G; Brodovsky HS; Horton J; Colsky J; Mansour EG; Creech R; Stolbach L; Greenspan EM; Levitt M; Israel L; Ezdinli EZ; Carbone PP
    Cancer Treat Rep; 1976 Jul; 60(7):925-32. PubMed ID: 1009523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The toxicity/efficacy relationship in polychemotherapy of lung neoplasms].
    Aapro MS; Alberto P; Forni M; Berchtold W; Sappino PA
    Schweiz Med Wochenschr; 1981 Mar; 111(12):414-21. PubMed ID: 6261322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four-drug combination chemotherapy in extensive non-small cell lung cancer: a Southwest Oncology Group Pilot Study.
    Livingston RB; Mira J; O'Bryan RM
    Cancer Treat Rep; 1981; 65(1-2):143-4. PubMed ID: 6164484
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP.
    Ruckdeschel JC; Mehta CR; Salazar OM; Creech RH; Sponzo RW
    Cancer Treat Rep; 1981; 65(11-12):959-63. PubMed ID: 6794909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
    Wagenaar HC; Colombo N; Vergote I; Hoctin-Boes G; Zanetta G; Pecorelli S; Lacave AJ; van Hoesel Q; Cervantes A; Bolis G; Namer M; Lhommé C; Guastalla JP; Nooij MA; Poveda A; Scotto di Palumbo V; Vermorken JB
    Gynecol Oncol; 2001 Jun; 81(3):348-54. PubMed ID: 11371121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine.
    Vogelzang NJ; Trowbridge RC; Frenning DH; Theologides A; Kennedy BJ; Kelly DR; Ewing SL; Vosika GJ
    Cancer Treat Rep; 1980; 64(8-9):997-1000. PubMed ID: 6256076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Random prospective study cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non small cell lung cancer.
    Einhorn LH; Williams SD; Stevens EE; Bond WH; Chenoweth L
    Cancer Treat Rep; 1982 Dec; 66(12):2005-11. PubMed ID: 6291763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung.
    Cambareri RJ; Smith FP; Macdonald JS; Haidak DJ; Ueno WM; Hoth DH; Woolley PV; Schein PS
    Cancer Treat Rep; 1981; 65(3-4):317-20. PubMed ID: 6263471
    [No Abstract]   [Full Text] [Related]  

  • 16. Nitrosourea combinations in lung cancer.
    Livingston RB
    Cancer Treat Rep; 1976 Jun; 60(6):757-760. PubMed ID: 182365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin, vincristine, bleomycin, cytembena and cisplatin as combination chemotherapy for squamous cell lung cancer.
    Georgoulias V; Misset JL; Ribaud P; Machover D; De Vassal F; Dorval T; Musset M; Schwarzenberg L; Reizenstein P; Mathe G; Gaget H
    Anticancer Res; 1983; 3(2):107-10. PubMed ID: 6189445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of modified Stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach.
    Newman SB; DeMeester TR; Golomb HM; Hoffman PC; Little AG; Raghavan V
    J Thorac Cardiovasc Surg; 1983 Aug; 86(2):180-5. PubMed ID: 6308356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
    Lanzotti VJ; Thomas DR; Holoye PY; Boyle LE; Smith TL; Samuels ML
    Cancer Treat Rep; 1976 Jan; 60(1):61-8. PubMed ID: 63331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Polychemotherapy in inoperable bronchial carcinoma].
    Schmidt CG
    Strahlentherapie; 1984 Feb; 160(2):71-6. PubMed ID: 6328699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.